Abivax Aktie
WKN DE: A14UQC / ISIN: FR0012333284
29.09.2023 18:00:09
|
EQS-News: Abivax announces the release of its 2023 half-year financial report
EQS-News: ABIVAX
/ Key word(s): Half Year Report
Abivax announces the release of its 2023 half-year financial report PARIS, France, September 29, 2023 6:00 p.m. (CEST) Abivax SA (Euronext Paris: FR0012333284 ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today the release of its 2023 half-year financial report. The 2023 half-year financial report is available on the website of the Company (www.abivax.com Investors).
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivaxs lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX_.
29.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1737263 29.09.2023 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Abivax SAmehr Nachrichten
25.07.25 |
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) (EQS Group) | |
24.07.25 |
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris (EQS Group) | |
24.07.25 |
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares (EQS Group) | |
24.07.25 |
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris (EQS Group) | |
23.07.25 |
EQS-News: Abivax Announces Launch of Public Offering (EQS Group) | |
11.06.25 |
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting (EQS Group) | |
02.06.25 |
EQS-News: Abivax Presents First Quarter 2025 Financial Results (EQS Group) | |
22.04.25 |
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors (EQS Group) |
Analysen zu Abivax SAmehr Analysen
Aktien in diesem Artikel
Abivax SA | 61,70 | 2,83% |
|